poisar

Stock

Cytokinetics, Incorporated CYTK

$73.19-0.35%

Overview

CYTK market data

Price History

CYTK price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$6.54
Diluted earnings per share over the trailing twelve months.
Beta
0.35
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,321.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$34.60 – $88.31
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $10.4B · P/B 15.68 · P/S 153.04.

Company News

10 captured
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110Benzinga · Aug 13, 2026, 6:09 PM
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103Benzinga · Aug 13, 2026, 3:04 PM
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are InvalidBenzinga · Aug 13, 2026, 1:35 PM
8-K filing — CYTOKINETICS INC (CYTK)SEC EDGAR · Aug 13, 2026, 1:25 PM
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112Benzinga · Aug 10, 2026, 5:45 PM
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112Benzinga · Aug 7, 2026, 6:43 PM
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110Benzinga · Aug 7, 2026, 2:25 PM
Needham Maintains Buy on Cytokinetics, Raises Price Target to $112Benzinga · Aug 7, 2026, 1:28 PM
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M EstimateBenzinga · Aug 6, 2026, 8:01 PM
Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult PatientsBenzinga · Jul 30, 2026, 10:21 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock